E78.0 E78.5
Conditions
Interventions
Group 1: Patients with statin therapy:
Blood was taken from all patients for NMR-lipid particle size detection.
Group 2: Patients with PCSK9-inhibitor therapy:
Blood was taken from all patients for
Sponsors
Benefit for Research on Arterial Hypertension, Dyslipidemia and Vascular Risk and Education - BRAVE e.V.
Eligibility
Sex/Gender
All
Age
18 Years to 85 Years
Inclusion criteria
Inclusion criteria: Patients suffering from severe hypercholesterolemia and/ or hyper-Lp(a)-emia will be included.
Exclusion criteria
Exclusion criteria: no specific exclusion criteria
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change of particel size in different lipid fractions undergoing different therapies like statins, PCSK9-I, lipoproteinapheresis; measured by nuclear magnetic resonance (NMR). All drugs are approved by Federal Institute for Drugs and Medical Devices (BfArM) and are not subjects to special conditions. | — |
Secondary
| Measure | Time frame |
|---|---|
| Prevention of a progress of coronary heart disease (CHD), cerebor vascular disease (CVD), peripheral arterial disease (PAD). The medical history will be recoreded with respect to changes of the vascular status. | — |
Countries
Germany
Contacts
Public ContactElke Schettler
Benefit for Research on Arterial Hypertension, Dyslipidemia and Vascular Risk and Education - BRAVE e.V.
Outcome results
None listed